Literature DB >> 19058767

High performance liquid chromatographic determination of plasma free and total tazobactam and piperacillin.

Gianna Di Giovamberardino1, Michele Ferrannini, Gian Piero Testore, Giorgio Federici, Anna Pastore.   

Abstract

A high-pressure liquid chromatography (HPLC) method with ultraviolet detection was developed for the measurement of plasma free and total tazobactam and piperacillin. This method is simple and fast, requiring only 11 min for the HPLC run and a sample preparation of about 11 min for total drugs and 10 min for free drugs. The procedure for the assay involves the treatment of plasma with acetonitrile for total drugs determination, and the use of a centrifugal filter device to deproteinize plasma for free drugs determination. The HPLC column, a Hypersil-ODS, was equilibrated with an eluent mixture composed of acetonitrile-potassium phosphate (pH 2.6). CVs for repeatability of tazobactam and piperacillin measurements ranged from 4.30 to 6.60; CVs for reproducibility ranged from 5.60 to 9.40. Mean analytical recoveries ranged from 100.4 to 103%. A linear relationship was obtained between peak area and drugs concentration in the range studied (0-62.5mg/L for tazobactam and 0-500mg/L for piperacillin). The equation for regression line were y=19x-1.4 for tazobactam and y=1.7x-0.9 for piperacillin; correlation coefficients were >0.999. The lower limit of quantitation (LLQ) for standard samples was about 0.12 mg/L for tazobactam and 0.49 mg/L for piperacillin, respectively. The lower limit of detection (LLD) was 0.06 mg/L for tazobactam and 0.24 mg/L for piperacillin. This HPLC assay for tazobactam and piperacillin is sensitive and accurate, and provides a reliable determination of both free and total tazobactam and piperacillin in human plasma, thus allowing the determination of these analytes in patients receiving tazocillin therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19058767     DOI: 10.1016/j.jchromb.2008.11.010

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

1.  Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis.

Authors:  Waroonrat Sukarnjanaset; Sutep Jaruratanasirikul; Thitima Wattanavijitkul
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-08       Impact factor: 2.745

2.  Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.

Authors:  Yewei Chen; Jinmiao Lu; Min Dong; Dan Wu; Yiqing Zhu; Qin Li; Chao Chen; Zhiping Li
Journal:  Eur J Clin Pharmacol       Date:  2016-09-19       Impact factor: 2.953

3.  Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.

Authors:  Rong Chen; Qing Qian; Meng-Ru Sun; Chun-Yan Qian; Su-Lan Zou; Ming-Li Wang; Li-Ying Wang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-08       Impact factor: 2.441

4.  Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa.

Authors:  T W Felton; J Goodwin; L O'Connor; A Sharp; L Gregson; J Livermore; S J Howard; M N Neely; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

5.  Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Simulation of Piperacillin/Tazobactam for Dosing Optimization in Late Elderly Patients with Pneumonia.

Authors:  Noriyuki Ishihara; Nobuhiro Nishimura; Kazuro Ikawa; Fumi Karino; Kiyotaka Miura; Hiroki Tamaki; Takahisa Yano; Takeshi Isobe; Norifumi Morikawa; Kohji Naora
Journal:  Antibiotics (Basel)       Date:  2020-03-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.